Elevance Health (ELV) Stock Still Looks Reasonable Despite Its 12% Gain

Elevance Health has delivered a 12.4% gain over the past year, even as shorter term moves have been choppy, and that raises a simple question for you as an investor. Is the current share price of the health benefits group adequately grounded in the earnings that support it, or has sentiment moved ahead of the underlying profit stream?

• The 12.4% return over the past year puts real weight on whether Elevance Health’s current earnings power can sustain that kind of shareholder experience.
• The company’s push to expand and refine its Medicare Advantage offerings, including more tailored plans for complex members, can influence future profitability by shifting the mix of earnings, the stability of cash flows, and the level of required investment.
• The analysts covering Elevance Health have run their own numbers. See what analysts think Elevance Health's shares could be worth.

The stock’s next move may depend on whether Elevance Health’s current earnings profile is strong enough to justify where the shares trade today.

If you want to test the same earnings question you are asking of Elevance Health across a broader group of stocks with similar traits, take a look at solid balance sheet and fundamentals stocks screener (26 results).

Is Elevance Health Still Cheap on Earnings?

The P/E ratio suits Elevance Health because earnings still sit at the center of how investors judge large, established insurers. On that measure, Elevance Health trades on about 16.9x earnings, compared with roughly 24.3x for the wider healthcare group and about 26.3x for peers in its comparison set. That is a sizable gap for a major managed care business where profits, not sales hype, tend to drive long term returns.

Because the modeled "fair" P/E for Elevance Health, which blends in its growth profile, margins, scale and risk, sits above the current multiple, the shares screen as undervalued on this framework. Despite the recent focus on expanded Medicare Advantage offerings for 2027, the current P/E still prices Elevance Health at a discount to both the sector and similar stocks, which suggests sentiment has not chased the story too far. Explore the numbers behind Elevance Health's P/E valuation.

The Elevance Health Narrative: What Would Justify Today's Price?

Narratives on Elevance Health act as the missing link between the current P/E puzzle and the assumptions that would need to hold on growth, margins and earnings for the stock to be worth materially more or less than today’s price. They sit on Simply Wall St’s Community page. Each scenario ties a fair value estimate to a clear storyline about Elevance Health's potential catalysts and key risks so you can see over time which version of events is actually taking shape.

One of the top community narratives on Elevance Health: 14% undervalued

"Ongoing deployment of Elevance Health’s AI, analytics and digital platforms such as HealthOS and Sydney Health, including automated prior authorization and earlier visibility into medical cost trends…"

Discover why this Narrative puts Elevance Health at 14% undervalued.

One more Elevance Health question that current valuation alone cannot answer

Price multiples tell you what Elevance Health is worth today, but broker models sketch where earnings and cash generation might go over the next few years, and how that lines up with this market tag. Explore where analysts expect Elevance Health to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com